UNSPSC 51401566: Lorazepam glucuronide

This classification denotes a benzodiazepine and antiemetic agent with the molecular formula C21H18Cl2N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0G8I56129, chemically known as .beta.-d-glucopyranosiduronic acid, 7-chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1h-1,4-benzodiazepin-3-yl, but more generally known as lorazepam glucuronide, which bears US NIH Compound Identifier 62966.

European Medicines Agency schedules lorazepam glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08582MIG. Most nations, for tariff purposes, schedule lorazepam glucuronide under HS 29339190. SMILES: C1CCC(C(C1)C2=NC(C(=O)NC3C2CC(CC3)CL)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CL.

UNSPSC 51401566 Lorazepam glucuronide is a Commodity code that nominally covers a specific pharmaceutical metabolite, but recent state and local solicitations tagged to this code are actually procuring naloxone, other generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles rather than lorazepam glucuronide itself. State and local health agencies, pharmacy benefit administrators, and cooperative purchasing alliances are the primary issuing bodies, seeking to establish supply agreements for emergency response medications and generic pharmaceutical inventories that support community health operations, employee health plans, and multi-state medicaid or public health programs.

Recent activity appears concentrated in Florida and Minnesota through cooperative purchasing and direct county procurement. Seminole County, Florida issued an IFB (IFB60459723LAS, response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with pricing weighted 75 percent on competitiveness and demanding compliance with cGMP and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription fulfillment models serving state employee health plans and self-insured groups. The code shows a significant mismatch between its pharmaceutical-metabolite name and actual procurement activity, which centers on emergency response supplies and generic pharmaceutical supply-chain management rather than this specific compound.